Page 153 - Read Online

Spiliopoulou et al. Cancer Drug Resist 2024;7:2 https://dx.doi.org/10.20517/cdr.2023.46 Page 21

biomarkers. Biotech Histochem 2018;93:411-23. DOI
77. Amgad M, Stovgaard ES, Balslev E, et al; International Immuno-Oncology Biomarker Working Group. Report on computational
assessment of Tumor Infiltrating Lymphocytes from the International Immuno-Oncology Biomarker Working Group. NPJ Breast
Cancer 2020;6:16. DOI PubMed PMC
78. Halse H, Colebatch AJ, Petrone P, et al. Multiplex immunohistochemistry accurately defines the immune context of metastatic
melanoma. Sci Rep 2018;8:11158. DOI PubMed PMC
79. Harms PW, Frankel TL, Moutafi M, et al. Multiplex immunohistochemistry and immunofluorescence: a practical update for
pathologists. Mod Pathol 2023;36:100197. DOI
80. Hsieh WC, Budiarto BR, Wang YF, et al. Spatial multi-omics analyses of the tumor immune microenvironment. J Biomed Sci
2022;29:96. DOI PubMed PMC
81. Andreatta M, Corria-Osorio J, Müller S, Cubas R, Coukos G, Carmona SJ. Interpretation of T cell states from single-cell
transcriptomics data using reference atlases. Nat Commun 2021;12:2965. DOI PubMed PMC
82. Höllbacher B, Duhen T, Motley S, Klicznik MM, Gratz IK, Campbell DJ. Transcriptomic profiling of human effector and regulatory
T cell subsets identifies predictive population signatures. Immunohorizons 2020;4:585-96. DOI PubMed PMC
83. Hui Z, Zhang J, Zheng Y, et al. Single-cell sequencing reveals the transcriptome and TCR characteristics of pTregs and in vitro
expanded iTregs. Front Immunol 2021;12:619932. DOI PubMed PMC
84. Cuadrado E, van den Biggelaar M, de Kivit S, et al. Proteomic analyses of human regulatory T cells reveal adaptations in signaling
pathways that protect cellular identity. Immunity 2018;48:1046-59.e6. DOI
85. Mensink M, Schrama E, Cuadrado E, Amsen D, de Kivit S, Borst J. Proteomics reveals unique identities of human TGF-β-induced
+
and thymus-derived CD4 regulatory T cells. Sci Rep 2022;12:20268. DOI PubMed PMC
86. Duguet F, Locard-Paulet M, Marcellin M, et al. Proteomic analysis of regulatory T cells reveals the importance of themis1 in the
control of their suppressive function. Mol Cell Proteomics 2017;16:1416-32. DOI PubMed PMC
87. Matheu MP, Othy S, Greenberg ML, et al. Imaging regulatory T cell dynamics and CTLA4-mediated suppression of T cell priming.
Nat Commun 2015;6:6219. DOI PubMed PMC
+
88. Kist de Ruijter L, van de Donk PP, Hooiveld-Noeken JS, et al. Whole-body CD8 T cell visualization before and during cancer
immunotherapy: a phase 1/2 trial. Nat Med 2022;28:2601-10. DOI PubMed PMC
89. Abdeladhim M, Karnell JL, Rieder SA. In or out of control: modulating regulatory T cell homeostasis and function with immune
checkpoint pathways. Front Immunol 2022;13:1033705. DOI PubMed PMC
90. Ballman KV. Biomarker: predictive or prognostic? J Clin Oncol 2015;33:3968-71. DOI
+
91. Shang B, Liu Y, Jiang SJ, Liu Y. Prognostic value of tumor-infiltrating FoxP3 regulatory T cells in cancers: a systematic review and
meta-analysis. Sci Rep 2015;5:15179. DOI PubMed PMC
92. Li L, Li Y, Yin Z, Zhu J, Yan D, Lou H. Increased frequency of regulatory T cells in the peripheral blood of patients with
endometrioid adenocarcinoma. Oncol Lett 2019;18:1424-30. DOI PubMed PMC
93. Kolben T, Mannewitz M, Perleberg C, et al. Presence of regulatory T-cells in endometrial cancer predicts poorer overall survival and
promotes progression of tumor cells. Cell Oncol 2022;45:1171-85. DOI PubMed PMC
94. Qiu J, Xu L, Zeng X, et al. CCL5 mediates breast cancer metastasis and prognosis through CCR5/Treg cells. Front Oncol
2022;12:972383. DOI PubMed PMC
+
95. Petersen RP, Campa MJ, Sperlazza J, et al. Tumor infiltrating Foxp3 regulatory T-cells are associated with recurrence in pathologic
stage I NSCLC patients. Cancer 2006;107:2866-72. DOI
+ - + +
96. Karagöz B, Bilgi O, Gümüs M, et al. CD8 CD28 cells and CD4 CD25 regulatory T cells in the peripheral blood of advanced stage
lung cancer patients. Med Oncol 2010;27:29-33. DOI
97. Erfani N, Mehrabadi SM, Ghayumi MA, et al. Increase of regulatory T cells in metastatic stage and CTLA-4 over expression in
lymphocytes of patients with non-small cell lung cancer (NSCLC). Lung Cancer 2012;77:306-11. DOI
+
-
+
98. Hu X, Gu Y, Zhao S, Hua S, Jiang Y. Elevated circulating CD4 CD25 Foxp3 regulatory T cells in patients with nonsmall cell lung
cancer. Cancer Biother Radiopharm 2019;34:325-33. DOI
+
99. Li S, Li Y, Qu X, Liu X, Liang J. Detection and significance of TregFoxP3 and Th17 cells in peripheral blood of non-small cell lung
cancer patients. Arch Med Sci 2014;10:232-9. DOI PubMed
+ + + + -
100. Chen C, Chen D, Zhang Y, et al. Changes of CD4 CD25 FOXP3 and CD8 CD28 regulatory T cells in non-small cell lung cancer
patients undergoing surgery. Int Immunopharmacol 2014;18:255-61. DOI
101. Kotsakis A, Koinis F, Katsarou A, et al. Prognostic value of circulating regulatory T cell subsets in untreated non-small cell lung
cancer patients. Sci Rep 2016;6:39247. DOI PubMed PMC
102. Luo JW, Guo YH, Wu FY, et al. Differences in immunological landscape between EGFR-mutated and wild-type lung
adenocarcinoma. Dis Markers 2021;2021:3776854. DOI PubMed PMC
103. Sugiyama E, Togashi Y, Takeuchi Y, et al. Blockade of EGFR improves responsiveness to PD-1 blockade in EGFR-mutated non-
small cell lung cancer. Sci Immunol 2020;5:eaav3937. DOI
104. Bjoern J, Juul Nitschke N, Zeeberg Iversen T, Schmidt H, Fode K, Svane IM. Immunological correlates of treatment and response in
stage IV malignant melanoma patients treated with Ipilimumab. Oncoimmunology 2016;5:e1100788. DOI PubMed PMC
105. Gambichler T, Schröter U, Höxtermann S, Susok L, Stockfleth E, Becker JC. Decline of programmed death-1-positive circulating T
regulatory cells predicts more favourable clinical outcome of patients with melanoma under immune checkpoint blockade. Br J